| Identification | Back Directory | [Name]
WYC-209 | [CAS]
2131803-90-0 | [Synonyms]
WYC-209
5-Pyrimidinecarboxylic acid, 2-[2-(3,4-dihydro-4,4-dimethyl-1-oxido-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester | [Molecular Formula]
C20H20N2O3S | [MOL File]
2131803-90-0.mol | [Molecular Weight]
368.45 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 83.33 mg/mL (226.16 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [color ]
Light yellow to yellow | [InChIKey]
LLMDAYVUHYVJSS-UHFFFAOYSA-N | [SMILES]
O=S1CCC(C)(C)C2=C1C=CC(C#CC3=NC=C(C(OCC)=O)C=N3)=C2 |
| Hazard Information | Back Directory | [Uses]
WYC-209 RAR Agonist is used in the preparation of the retinoid compounds and their application as anticancer agents. | [Biological Activity]
Synthetic retinoid with antiproliferative activity''WYC-209 is a synthetic retinoid with antiproliferative activity and better inhibition of cancer cell growth and proliferation than Tazarotene or ATRA (all-trans-retinoic acid). WYC-209 was shown to inhibit proliferation of malignant murine melanoma tumor-repopulating cells (TRCs) with an IC50 value of 190 nM and also inhibited proliferation of TRCs of human melanomalung cancerovarian cancerand breast cancer in culture. | [in vivo]
WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases[1]. | Animal Model: | Female immune-competent C57BL/6 mice[1] | | Dosage: | 0.022, 0.22?mg/kg | | Administration: | Intravenous injection; once every two days for 25 days | | Result: | Four out of eight mice formed lung metastases at dose of 0.022?mg?/kg, only one out of eight mice formed lung metastases at dose of 0.22?mg/kg. |
|
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|